Where Unicycive Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Unicycive Therapeutics (NASDAQ:UNCY) has received mostly bullish ratings from analysts in the last quarter. The company has an average price target of $5.75, down by 23.33% from the previous average price target of $7.50.
August 16, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Unicycive Therapeutics has received mostly bullish ratings from analysts, but the average price target has decreased by 23.33%.
The company has received mostly bullish ratings from analysts, indicating a positive outlook. However, the decrease in the average price target could suggest that analysts are less optimistic about the company's future performance than they were previously.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100